Get started

CBIS

ProjeXions Series - Vol1 - Cannabis Industry - CBIS, 2-YEAR, OTCThis is a work-flow experiment. The details surrounding the indicators and metrics used to arrive at my conclusions will be discussed when my targets are met. Cannabis Science, Inc. takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on cancers, HIV/AIDS, and neurological conditions. The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.
C
by ZpaceBuddha
MJNA Target 0.50 - 1.00This stock is pretty much looked at as the otc ETF for the marijuana sector. Target based on the sector. The other targets I have mentioned are based on company financials and fundamentals Business Description Medical Marijuana Inc. (OTC Pink Sheets; MJNA) is the first publicly held company vested in the cannabis and industrial hemp space in America. Through its subsidiaries and investment holdings the Company focuses on the development, sale and distribution of hemp oil that contains naturally occurring cannabinoids, including cannabidiol ("CBD") and other products containing CBD-rich hemp oil ("Legal Hemp"). Company products are formulated for the pharmaceutical, nutraceutical and cosmeceutical industries, including dietary supplements, prescription-based hemp oil for sale in countries that have legalized our hemp oil for the treatment of various illnesses and conditions (such as Brazil and Mexico) and skin care products. The Company is not in the business of selling or dispensing either recreational or medical marijuana, directly or indirectly, so long as marijuana remains a federally controlled substance, however, we are poised and consider ourselves well-positioned for eventual cannabis legalization (the Company's products contain only those substances that are derived from the part of the cannabis plant that is excluded from the definition of marijuana under the Controlled Substances Act and are both federally legal and outside of the purview of the Drug Enforcement Administration). Medical Marijuana, Inc. and Subsidiaries HempMeds® Mexico, HempMeds® Brazil and Kannaway® Announce 2017 as the Largest Revenue Year in Company History PR Newswire SAN DIEGO, Jan. 8, 2018 SAN DIEGO, Jan. 8, 2018 /PRNewswire/ -- Medical Marijuana, Inc. (OTC: MJNA), the first-ever publicly traded cannabis company in the United States, today announced that the Company and its subsidiaries HempMeds® Mexico, HempMeds® Brazil and Kannaway® generated the largest-ever (unaudited) revenue year in its history in 2017, as well as reached major milestones in its business operations. In 2017, Medical Marijuana, Inc. had a number of significant accomplishments, including: Experienced year over year revenue growth of more than 300% compared to 2016 Medical Marijuana, Inc. CEO Dr. Stuart Titus spoke at several national and international cannabis conferences including A4M Mexico, the California Cannabis Business Expo, World Medical Cannabis Conference & Expo, ExpoWeed, the International Fair of Medical Cannabis and the Marijuana Business Conference & Expo Announced the promotion of Vice President of Operations, who also serves as Kannaway CEO, Blake N. Schroeder, Esq., to Chief Operating Officer Appointed Alex Grapov as new International Vice President, Jim Gibson as new Vice President of Operations and Stephen Jones as Chief Marketing Officer Medical Marijuana, Inc. subsidiary Kannaway® was the first direct sales company to offer phyto-cannabinoid botanical products to consumers. A family-oriented company, Kannaway® encourages its brand ambassadors to create their own successful distribution businesses that will positively benefit the wellbeing of the people around them. In 2017, Kannaway® had a number of significant accomplishments including: Launched new products including a Hempy's® line of clothing products, Kannaway® Energy Chews, Kannaway® Essential Oils, updated HempVAP® Terpene-infused Vape, Kannaway® SuperGreens and Kannaway® Pure Gold Announced international expansion with the establishment of Kannaway® Europe Experienced year over year revenue growth of more than 500% compared to 2016 Achieved the largest sales year in its history. HempMeds® Mexico is Medical Marijuana, Inc.'s distribution branch in the country, focusing on providing non-psychoactive cannabidiol (CBD) products to the people of Mexico. HempMeds® Mexico was the first company to have a medical cannabis product approved for import into Mexi
OTC:MJNALong
by StockPicksNYC98
$OWCP Bullish Pennant Formation with Upcoming MJ Catalysts News ANNUAL REPORT CLARIFICATION FOR SHAREHOLDERS: 1) Page 5: Don't get confused by the OWCP already done Psoriasis study (where efficacy results are imminent) and next deeper and extended studies planned from April: "On February 1, 2017, following the very encouraging results that have been achieved at the mid-point of the Study, the Company determined to extend the size and scope of the Study for the purpose, among other things, of checking the biological markers that have been generated to date with respect to the treatment of psoriasis (proliferation/ inhibition and several interleukins). Despite extending its size and scope of the Study, the Registrant expects to compete the Study during the 2 nd or 3 rd quarters of 2017." The study already done is confirmed in page 36: "We have been conducting a study on the efficacy of the cannabinoid-based topical cream for the treatment of skin conditions generally and psoriasis specifically, which commenced in November, 2016 " While the extended study to start in April 2017 according to previous 8K is the safety phase and identification of biological markers useful to identify potential other application of the cream (Skin Cancer imo): "We started safety phase at the hospital by this month, April 2017, and already planning a unique multi-center efficacy study. This is the natural development of the next generation of safe and tested cannabinoids treatments" 2) Page 5-6: Multiple Myeloma Amazing News for Shareholders is here: "Dr. Leiba led our in vitro studies on the effect of a formulation comprised of Cannabidiol (CBD) and tetrahydrocannabinol (THC) on multiple myeloma cells studied outside their normal biological context. The results indicated a 100% mortality rate of myeloma cells in 80% of the cultured cells within a 24 to 48-hour period, and highlight the potential abilities of cannabis oil extract to fight multiple myeloma cancer cells. We believe that the results of this study indicate a potential to develop a more effective treatment for multiple myeloma than standard therapies." "Expect to submit a clinical trial protocol to the Israeli Institutional Review Board and received its approval to commence a clinical study" "Intend to commence a clinical study in the third quarter of 2017" 3) Notes on competition page 7: For Psoriasis they aim to attack Big Pharma market and they are well aware of current products and thier limitation: "The current common treatments for psoriasis include topical and systemic drugs, steroids, immunosuppressive drugs such as Cyclosporine A (by Novartis), methotrexate or MTX and biological drugs such as Enbrel (by Amgen), Amevive (by Biogen but whose patent expired in 2013) and Ustakinumabn (by Janssen Immunology)." This is excelent Marketing strategic approach; 4) Page 8: Provisional Patents are listed in report, can be downloaded through reference number and are real! They are extremely well written in a professional way and full of interesting claims: when needed (close to deadline) they will pay the service fees and transform them in Official US Permanent Patent; Why to do it before if the provisional is free of charge? Smart approach; 5) Page 12: CERTIFICATION and FDA approval all diligently work has been done according to standard: " Israel’s Ministry of Health, which regulates medical testing, has adopted protocols that correspond, generally, to those of the FDA and the EMA, making it comparatively straightforward for studies conducted in Israel to satisfy FDA and the European Medicines Agency requirements, thereby enabling medical technologies subjected to clinical trials in Israel to reach U.S. and EU commercial markets in an expedited fashion. Many members of Israel’s medical community have earned international prestige in their chosen fields of expertise and routinely collaborate, teach and lecture at leading medical centers throughout the world. Israel also has free trade agreements with the United States
OTC:OWCPLong
by StockGuild
$ATTBF History Repeats Itself 2014 Run from .0125 to $2.85Remember the first MJ Rush in 2014? $ATTBF one of the few stocks HQ'ed in Canada but traded in America with its second symbol went from .0125 to $2.85 on Colorado recreationally legalizing MJ back in 2012 and the law was implemented that year and a few others legalized it recreationally and medically as well. Well now that beautiful rush has come full circle once again. Those states that legalized it that year implemented it last year and those profits will be on balance sheets this year, in addition Canada is going to approve recreationally Marijuana legally across their entire country on April 20th. With $ATTBF HQ'ed in Canada this is the green gold everyone will be waiting for. MJ stocks will shoot up, but MJ stocks from Canada will more than likely shoot even higher. $ATTBF has the best of both worlds, Bio and Medical Marijuana and other MJ products, a beautiful marriage of everything we love in both worlds. The chart and technical are primed for a beautiful run upwards. I would not say its outrageous to suggest a PPS target of $3.00 or more this time around. As can be seen, this stock has shown true strength and movement when it wants to.
OTC:ATTBFLong
by StockGuild
The entire sector has fallenThe entire Cannabis OTC sector seems to be in absolute peril the last few days. I know many are cutting their losses and getting out, so forgive me for being a bit of a bag holder now and and buckling in for the storm. I do not know how much further down this will go, nobody does. I've lost about $800 or so since opening today on this stock, but I'm still going to gamble here and hold this through Jan/Feb and reevaluate then. I don't know why we're dumping across the sector this week, other than people bought the hype and sold the news. Looking at MJNA's lifetime chart, some of the historic runups in price came Jan/Feb so I'm optimistic for the future of Cannabis as an investment. I don't think 2 days of straight dumps after legalization in some major states is representative of the sector as a whole long term. Lets see. If you're holding with me, buckle up!
OTC:MJNALong
by Cryptocol
2